Mau Ern Poh, Chee Shee Chai, Chong Kin Liam, Gwo Fuang Ho, Yong Kek Pang, Harissa Husainy Hasbullah, Lye Mun Tho, Ibtisam Muhamad Nor, Kean Fatt Ho, Muthukkumaran Thiagarajan, Azlina Samsudin, Azza Omar, Choo Khoon Ong, Sing Yang Soon, Sin Nee Tan, Soon Hin How
BACKGROUND: Afatinib can be started at a dose lower than the recommended starting dose of 40 mg/day for the treatment of epidermal growth factor receptor ( EGFR )-mutant non-small cell lung cancer (NSCLC), however treatment outcomes in real-world clinical practice remains unclear. METHODS: This retrospective study of patients with NSCLC from 18 major hospitals (public, private or university teaching hospitals) enrolled in Malaysia's National Cardiovascular and Thoracic Surgical Database (NCTSD) assessed the efficacy of lower doses of afatinib on treatment outcomes in a real-world clinical practice...
February 29, 2024: Translational Lung Cancer Research